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Background: At recurrence the use of nitrosoureas is widely-used as a therapeutic option for glioblastoma (GBM)
patients. The efficacy of fotemustine (FTM) has been demonstrated in phase II clinical trials; however, these papers
report a wide range of progression-free-survival (PFS-6 m) rates, ranging from 21% to 52%. We investigated whether
FTM could have a different response pattern in respect to time to adjuvant temozolomide failure, or whether
specific independent risk factors could be responsible for the wide range of response rates observed.
Methods: Recurrent GBM patients have been treated with fotemustine 75-100 mg/sqm at day 1, 8, 15 and after 4/
5 weeks of rest with 100 mg/sqm every 21 days. Patients were stratified in 4 groups according to time to
temozolomide failure: before starting (B0), during the first 6 months (B1), after more than 6 months of therapy (B2),
and after a treatment-free interval (B3). Primary endpoint was PFS-6 m. A multivariable analysis was performed to
identify whether gender, time after radiotherapy, second surgery and number of TMZ cycles could be independent
predictors of the clinical benefit to FTM treatment.
Results: 163 recurrent GBM patients were included in the analysis. PFS-6 m rates for the B0, B1, B2 and B3 groups
were 25%, 28%, 31.1% and 43.8%, respectively. The probability of disease control was higher in patients with a
longer time after radiotherapy (p = 0.0161) and in those who had undergone a second surgery (p = 0.0306).
Conclusions: FTM is confirmed as a valuable therapeutic option for patients with recurrent GBM and was active in
all study patient groups. Time after the completion of radiotherapy and second surgery are independent treatment-
related risk factors that were predictive of clinical benefit.
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Glioblastoma (GBM) is the most common malignant
primary brain tumor in adults and is associated with a
poor prognosis [1]. Radiotherapy, plus concomitant and
adjuvant temozolomide (TMZ), is the standard first line
treatment given to GBM patients, as defined in the
EORTC trial [2,3]. On recurrence of the tumor, patients
have few therapeutic options – nitrosoureas, alternative* Correspondence: ivanlolli1@tin.it
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reproduction in any medium, provided the orTMZ schedules, and new target therapies, but prognosis
remains poor [4].
Novel target therapies, including antiangiogenic drugs,
are under investigation, but the role of such drugs in the
treatment of GBM is still being debated [5]. Research is
needed to establish the most advantageous combination
regimens containing antiangiogenic or target therapies
[6].
Rechallenge with TMZ is often used following GBM
recurrence, but its usefulness is questionable due to con-
flicting data [7-9]. Recently, Perry and colleagues [10]
have demonstrated that time to adjuvant temozolomidetral Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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ment. Continuous high-dose TMZ is used in patients
who relapse after standard therapy, notably in those
patients with early or late progression after standard
therapy.
Fotemustine (FTM) is a third-generation chloroethyl-
nitrosourea containing a phosphoalanine carrier group
attached to the nitrosourea radical [11]. This characteris-
tic allows FTM to cross the blood–brain barrier (BBB),
as shown by experimental studies in animals [12-14]. In
addition, as FTM does not significantly alter glutathione
reductase activity, a more favorable pulmonary toxicity
profile for this agent can be predicted compared with
BCNU [15]. During a conventional treatment schedule,
FTM is administered as induction therapy at a dose of
100 mg/m2/week for three consecutive weeks, followed
by maintenance therapy of 100 mg/m2 every three
weeks, after a 5-week rest [16]. Several Italian groups
investigated the efficacy of FTM in malignant glioma
patients experiencing tumor recurrence after standard
TMZ treatment. In these reports, the 6-months
progression-free survival (PFS-6 m) rates ranged from
21 to 52% [17-19]. Despite the homogeneous patient
population in these studies (patients with the first recur-
rence of GBM after initiation of the Stupp regimen2),
there was a high variability in the PFS-6 m rate. To jus-
tify this data, different hypotheses have been formulated.
For example, the presence of patients experiencing pseu-
doprogression [20], as suggested recently by Silvani and
colleagues [16], resulting in a different response pattern
related to time of adjuvant TMZ failure, or the presence
of patient- or treatment-specific risk factors in the study
population.
Based on these assumptions, the aim of the present
retrospective analysis was to assess whether FTM could
have a different response pattern compared to the time
to adjuvant TMZ failure, or whether specific independ-
ent risk factors could be responsible for the wide range
of survival rates observed.
Methods
Six Italian sites participated in this retrospective pooled
analysis. The study was done in accordance with the
provisions of the Declaration of Helsinki and local regu-
lations. The study was approved by the institutional re-
view board at each study centre.
Adult patients with recurrent or progressive,
histologically-confirmed GBM who underwent surgery
and the Stupp regimen (radiotherapy plus concomitant
and adjuvant temozolomide) [2] were included in the
analysis. Progression was documented by MRI or com-
puted tomography (CT) scans. All patients received
1 h intravenous infusion of FTM according to the fol-
lowing schedule: induction phase dose of 70–100 mg/m2 on days 1, 8, 15, followed by a 4/5-week rest
period, and a maintenance phase dose of 100 mg/m2
every 21 days.
Contrast-enhanced (gadolinium-DTPA 0.2 mmol/kg)
MRI of the brain was uniformly adopted for tumor as-
sessment and response evaluation. Baseline MRI exam-
ination was performed before administration of FTM,
and subsequent evaluations were carried out after com-
pletion of the induction phase, every two cycles during
the maintenance phase.
Glioblastoma patients were stratified into three groups
according to time to TMZ failure, as proposed by Perry
and colleagues10. Group B1 (early): progression while
receiving adjuvant TMZ before completion of six cycles
of adjuvant TMZ. Group B2 (extended): progression
while receiving extended adjuvant TMZ beyond the
standard six cycles, but before completion of the adju-
vant treatment. Group B3 (rechallenge): progression
after completion of TMZ.
We added a fourth group, B0: progression after radio-
therapy completion and before initiation of adjuvant
TMZ. Response was assessed clinically and radiologically
using evaluated with Macdonald’s criteria [21]. Safety was
evaluated during the study and all adverse events were
recorded and graded according to the common termin-
ology criteria for adverse events (CTCAE) from the Na-
tional Cancer Institute, version 4.0. (http://ctep.cancer.
gov/forms/CTCAEv4.pdf).
The primary endpoint of the study was evaluation of
progression-free survival at six months (PFS-6 m)
according to time of TMZ failure (B0, B1, B2, B3).
Secondary endpoints were evaluated in all four patient
groups, plus the whole population, and were: response
rate (RR), disease control (DC), overall survival at 1 year
(OS-1y) and time to progression (TtoP). Responses were
confirmed as complete (CR), partial (PR) and stable
(SD). RR was defined as CR + PR, otherwise DC is
defined as CR + PR + SD. OS was measured from the
start of FTM to death for any reason, or last follow-up
assessment. Disease progression (DP) was confirmed
with two consecutive radiologic investigations.
A multivariable analysis of the whole population was
performed to identify whether gender, time after radio-
therapy, second surgery and number of TMZ cycles
could be independent predictors of clinical benefit (DC)
to the FTM treatment. The multivariable model was
built adopting the so-called epidemiological approach,
which consists of selecting covariates regardless of uni-
variate findings or statistical elimination methods (back-
ward, stepwise, forward etc) but depending only on their
expected or potential clinical importance. Time to pro-
gression and time to death, in the whole population, was
estimated by Kaplan-Meier analysis between responder
and non-responder patients.
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The demographic and clinical-pathological characteris-
tics were summarized using descriptive statistics. In
general, absolute and relative frequencies were employed
to summarize qualitative variables, while arithmetic
mean, standard deviation (SD), range, median and inter-
quartile range were used to summarize quantitative
data.
Penalized multivariable logistic regressions with gen-
der, time from radiotherapy, second surgery, and num-
ber of TMZ cycles as covariates were performed
adopting the Firth’s correction in order to adjust esti-
mates for potential over-fitting, skewed data and multi-
collinearity. Results were reported as adjusted
(penalized) odds ratios (ORs) with an associated 95%
CI and two-tailed probability values. Statistical calcula-
tions were carried out using SAS version 9.2. A two-
tailed P-value of 0.05 was used to define statistically
significant results.Table 1 Patient characteristics according to time of TMZ failu
Variable B0 B1
Number of pts 20 50
Age years
Median (range) 59.5(50 -65) 57.5(47 - 64)
Gender % (N)
Male 70 (14) 64 (32)
Female 30 (6) 36 (18)
Type of Surgery at diagnosis % (N)
Biopsy 0 4 (2)
Partial 55 (11) 36 (18)
Complete 45 (9) 60 (30)
RPA at baseline % (N)
III 5 (1) 14 (7)
IV 90 (18) 68 (34)
V 5 (1) 18(9)
Number of adjuvant TMZ
Cycles, Mean (range) 0 3 (2 – 4)
Time after end of radiation
Months, Mean (range) 1(0.7 - 1.2) 4.2(3.1 - 5.1)
Surgery at recurrence % (N)
No 95 (19) 88 (44)
Yes 5 (1) 12 (6)
FTM induction dosage (mg/m2)
Median (range) 95(80– 100) 100(80 – 100)
FTM administration number
Median (range) 4 (3 – 11) 4 (1 – 18)
FTM: fotemustine TMZ: temozolomide; RPA: recursive partitioning analysis; B0: patie
patients failing during the first 6 months of adjuvant TMZ; B2: patients who failed a
recurrence after a treatment-free interval.Results
One hundred and sixty-three patients with a diagnosis
of recurrent GBM were included in the analysis. All
patients followed a Stupp regimen as first line treat-
ment; all patients were treated with a combination of
radiotherapy and TMZ, 87.7% (143/163) received adju-
vant TMZ, and 12.3% (20/163) of patients experienced
a recurrence immediately following the conclusion of
radiotherapy and were thus evaluated as the B0 group.
Patient characteristics are listed in Table 1 for the
whole population according to time of adjuvant TMZ
failure stratification: 12.3% (20/163), 30.7% (50/163),
27.6% (45/163), 29.4% (48/163) were divided into the
B0, B1, B2, B3 groups, respectively. Most patients were
male (66.9%) with a median age of 57 years (range
47–66). All patients were included in the efficacy and
safety analysis.
All patients received at least one dose of the study
drug, with a median number of 4 administrations up to are for the entire population
B2 B3 All
45 48 163
57(49 - 66) 57(47 - 65) 57(47 - 66)
64.4 (29) 70.8 (34) 66.9 (109)
35.6 (16) 29.2 (14) 33.1 (54)
2.2 (1) 2.1 (1) 2.5 (4)
44.4 (20) 39.6 (19) 41.7 (68)
53.3 (24) 58.3 (28) 55.8 (91)
17.8 (8) 31.3 (15) 19 (31)
73.3 (33) 66.7 (32) 71.8 (117)
8.9 (4) 2 (1) 9.2 (15)
9 (7 – 11) 6.5 (6 – 11) 6 (2 – 8)
8.9(6.7 - 11.4) 14.1(10.7 - 25.7) 6.8(3.9 - 12)
80 (36) 75 (36) 82.8 (135)
20 (9) 25 (12) 17.2 (28)
100(80 – 100) 75(75 – 100) 100(75 – 100)
3 (1 – 18) 5 (1 – 20) 4 (1 – 20)
nts failing after radiotherapy completion and before starting adjuvant TMZ; B1:
fter more than 6 months of therapy; B3: patients who experienced tumor
Table 2 Response to FTM treatment according to time of TMZ failure for the entire population
Variable B0 B1 B2 B3 All
Number of pts 20 50 45 48 163
Response to FTM % (N)
CR 0 2 (1) 2.2 (1) 2.1 (1) 1.8 (3)
PR 15 (3) 10 (5) 15.6 (7) 16.7 (8) 14.1 (23)
SD 30 (6) 24 (12) 24.4 (11) 47.9 (23) 31.9 (52)
DP 55 (11) 64 (32) 57.8 (26) 33.3 (16) 52.1 (85)
Disease Control % (N)
Yes 45 (9) 36 (18) 42.2(19) 66.7 (32) 47.8 (78)
PFS-6 m% (N)
Yes 25 (5) 28 (14) 31.1 (14) 43.8 (21) 33.1 (54)
OS-1y % (N)
Yes 25 (5) 24 (12) 28.9 (13) 31.3 (15) 27.6 (45)
Time to DP after FTM
Days median (range) 111(83 - 182) 91(43 - 156) 104(58 - 190) 139(62 - 252) 104(58 - 193)
CR: complete response; PR: partial response; SD: stable disease; DP: disease progression; PSF-6 m: progression free survival at 6 months; OS-1y: overall survival at
1 year; FTM: fotemustine. B0: patients failing after radiotherapy completion and before starting adjuvant TMZ; B1: patients failing during the first 6 months of
adjuvant TMZ; B2: patients who failed after more than 6 months of therapy; B3: patients who experienced tumor recurrence after a treatment-free interval.
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100 mg/m2 of FTM was the median administered dosage
(range 75–100).
Response to FTM treatment was documented in all
patients (Table 2). The PFS-6 m rate, the primary end-
point of the study, was reported in 25.0% of B0, 28.0% of
B1, 31.1% of B2 and 43.8% of B3.
RR was reported as 15.0%, 10.0%, 15.6% and 16.7% of
the B0, B1, B2 and B3 groups respectively. The DC rate
ranged from 36.0% (B1) to 66.7 (B3), while OS-1y ranged
from 25.0% (B0) to 31.3% (B3).
The multivariable logistic regression evaluated the
impact of gender, time from radiotherapy, second sur-
gery, and number of TMZ cycles on DC in the whole
population (Table 3). The probability of DC was higher
in patients with a longer time from radiotherapy (OR±
95% CI: 1.075, 1.019-1.147; p = 0.0161) and in those
who underwent a second surgery (OR± 95% CI: 2.802,
1.152-7.334; p = 0.0306).Table 3 Multivariable penalized logistic regression using Firth
Response variable = Disease control (CR + PR + SD)
Effect Odds ratio Lower 95% Confi
Gender - Female vs Male 0.906 0.452
Second Surgery 2.802 1.152
Time from radiotherapy 1.075 1.019
Number of TMZ cycles 0.925 0.838
Response variable is Disease control (CR + PR + SD). Odds ratios for time from radiot
associated with an increase of 1 month in time from radiotherapy and the deterioraFTM administration was well tolerated and the most
relevant grade 3–4 toxicity events were leucopenia
(6.7%) and thrombocytopenia (9.8%), as expected. No
differences in tolerability were observed between study
groups (Table 4). None unexpected toxicity has been
detected in the study population.Discussion
Recurrent glioblastoma has an unfavorable prognosis,
with a PFS-6 m rate ranging from 15% to 21%, and a
median survival of 25 weeks. The optimal strategy for
recurrent glioblastoma has not yet been defined [22].
Nitrosourea chemotherapy, carmustine and FTM, and
alternative TMZ treatment regimes are often used on re-
currence of the tumor [4]. Patients treated with carmus-
tine at a dose of 80 mg/m2 on days 1 to 3 (repeated
every 3 weeks for a maximum of 6 cycles) had a 13%
PFS-6 m rate and a median OS of 22 weeks [23].’s correction
dence Limit Upper 95% Confidence Limit P-Value
1.800 0.7806
7.334 0.0306
1.147 0.0161
1.013 0.1053
herapy and number of TMZ cycles show an improvement ratio (OR> 1)
tion ratio (OR< 1) associated with an increase of 1 cycle in number of TMZ.
Table 4 Patient safety profile according to time of
temozolomide failure, and for the entire population
Variable B0 B1 B2 B3 All patients
Number of patients 20 50 45 48 163
Leucopoenia
G 0 65 (13) 78 (39) 68.9 (31) 62.5 (30) 69.3 (113)
G 1-2 20 (4) 20 (10) 18.9 (13) 25 (12) 23.9 (39)
G 3-4 15 (3) 2 (1)* 2.2 (1)* 12.5 (6) 6.7 (11)
Thrombocytopenia
G 0 65 (13) 52 (26) 62.2 (28) 66.7 (32) 60.7 (99)
G 1-2 25 (5) 38 (19) 35.6 (16) 16.6 (8) 19.4 (48)
G 3-4 10 (2) 10 (5) 2.2 (1)* 16.7 (8) 9.8 (16)
Anemia
G 0 80 (16) 96 (48) 93.3 (42) 97.9 (47) 93.9 (153)
G 1-2 15 (3) 2 (1) 6.6 (3) 2.1 (1) 5 (8)
G 3-4 5 (1)* 2 (1)* 0 0 1.2 (2)*
Neutropenia
G 0 90 (18) 94 (47) 100 (45) 75 (36) 89.6 (146)
G 1-2 5 (1) 6 (3) 0 12.5 (6) 6.1 (10)
G 3-4 5 (1) 0 0 12.5 (6) 4.3 (7)
Lymphopenia
G 0 100 (20) 92 (46) 100 (45) 77.1 (37) 90.8 (148)
G 1-2 0 6 (3) 0 14.6 (7) 6.1 (10)
G 3-4 0* 2 (1)* 0* 8.4 (4) 3.1 (5)
Hepatic
G 0 80 (16) 96 (48) 95.6 (43) 93.8 (45) 93.3 (152)
G 1-2 20 (4) 2 (1) 4.4 (2) 4.2 (2) 5.5 (9)
G 3-4 0 2 (1) 0 2.1 (1) 1.2 (2)
*No grade 4 toxicity was detected. B0: patients failing after radiotherapy
completion and before starting adjuvant TMZ; B1: patients failing during the
first 6 months of adjuvant TMZ; B2: patients who failed after more than
6 months of therapy; B3: patients who experienced tumor recurrence after a
treatment-free interval.
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TMZ has been questionable, due to conflicting data
[5-7], but recently the RESCUE trial [10] demonstrated
that time to adjuvant TMZ failure could influence the re-
sponse to TMZ treatment on tumor recurrence: PFS-6 m
rates were 27.3%, 7.4%, 35.7%, while OS-1y rates were
27.3%, 14.8%, and 28.6% for patients failing during the
first 6 months of adjuvant TMZ (B1), those who failed
after more than 6 months of therapy (B2), and those who
experienced a recurrence after a treatment-free interval
(B3), respectively. Continuous high-dose TMZ seems
more effective in the B1 and B3 groups [10].
FTM is a third generation nitrosourea with more fa-
vorable efficacy and safety profile compared with car-
mustine [24]. Recently, several phase II trials studied the
use of FTM in malignant glioma patients recurring afterfollowing the Stupp regimen [17-19], but in these papers
the efficacy of FTM was associated with a wide range of
PFS-6 m rates, ranging from 21% to 52%, while the DC
ranged from 42.5% to 62%. To justify this range, we
assumed that efficacy of FTM could have a different re-
sponse pattern in respect to time to adjuvant TMZ fail-
ure, or that specific independent risk factors could
influence the drug activity. We retrospectively reviewed
recurrent GBM patients treated with FTM and having
received a Stupp regimen, and stratified them accord-
ingly to time to TMZ failure.
In our analysis, FTM was active in all patient groups,
with a higher response to the nitrosourea treatment
trend in patients who experienced tumor recurrence
after a treatment-free interval. For these patients, the
PFS-6 m rate was 43.8%, the OS-1y rate was 31.3%, the
RR was 18.8% and the DC was 66.7%. The hypothesis
that a higher response to FTM treatment could be due
to the presence of patients in the pseudoprogression16
phase seems not to be justified in our patient series.
Patients who relapsed near the end of radiotherapy (B0
group) were those with the lowest clinical response for
all study endpoints: PFS-6 m (25.0%), OS-1y (25.0%),
and RR (15.0%).
A comparison between our data and those reported
by Perry could suggest a potentially different response
pattern between recurrent GBM patients treated with
FTM and those with TMZ, in respect to adjuvant TMZ
failure. TMZ is active in early and late progression
patients, while FTM was always active in recurrent
patients: the PFS-6 m, OS-1y, RR and DC rates are
reported in Figure 1. The greatest difference between
the two treatments appears to be in the B2 group
where FTM and TMZ have a different pattern of activ-
ity: PFS-6 m rates were 31.1% and 7.4%, OS-1y rates
were 28.9% and 14.8%, RRs were 17.8% and zero, DCs
were 42.2% and 7.7%.
Hypothetically, the different response pattern between
patients treated with FMT and those with TMZ could be
due to the different mechanism of action between the
two alkylating agents. FTM, unlike TMZ, a known
mono-functional DNA methylating agent, is a mono-
functional/bi-functional agent containing a chloroethy-
lating group11, acting through a mechanism largely
based on DNA interstrand cross-linking [25].
The multivariable analysis investigated whether
patient- (gender) or treatment- (time after radiation,
number of TMZ cycles, second surgery) specific risk fac-
tors could be predictive of the FTM clinical benefit.
Results of the multivariable analysis demonstrated that
time after radiotherapy and second surgery are predictive
of a DC in patients treated with FTM. In Figure 1 it can
be appreciated how all clinical endpoints (PFS-6 m, OS-
1y, RR and DC) occur at a higher rate in patients who
Figure 1 Comparison between TMZ and FTM. FTM: fotemustine;
TMZ: temozolomide; B1: GBM patients failing during the first
6 months of adjuvant TMZ; B2: GBM patients who failed after more
than 6 months of therapy; B3: GBM patients who experienced tumor
recurrence after a treatment-free interval.
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with the lowest values are those in the B0 group.
In the light of these results, we could hypothesize that
the conflicting data in the FTM trials could be due to
the inclusion of higher risk patients. The GICNO study
[17] also included patients who did not start adjuvant
TMZ, while the Scoccianti [18] and Fabrini [19] studies
included only patients who started adjuvant TMZ and
where tumor recurrence was at least 3 months after the
end of radiotherapy.
Recently the EORTC Brain Tumour Group analysed
retrospectively data from 300 patients with recurrent
GBM, from phase I or II trials, to evaluate patient’s age,
sex, World Health Organisation (WHO) performance
status (PS), presence of neurological deficits, disease his-
tory, use of steroids or anti-epileptics and disease char-
acteristics to predict PFS and OS. This study confirms
performance status but not age as a major prognostic
factor for PFS and OS in recurrent GBM patients ini-
tially treated by chemoradiation with temozolomide [26].
Future prospective studies could confirm if these inde-
pendent positive risk factors noticed in the EORTC trial
and those of our study, could be find also in patients
treated with other chemotherapy agents both for naïve
and recurrent GBM patients.
Our study is biased in that the analysis was carried out
retrospectively, and that the MGMT status data for the
patients experiencing tumor recurrence is missing; how-
ever, we know that the methylation status of the pro-
moter is prognostic at the time of diagnosis [27], but
does not seem to be predictive of outcome at recurrence
of GBM [28].Conclusions
FTM is confirmed as a valuable therapeutic option for
patients with recurrent GBM (PFS-6 m= 33.1%), and is
active in all study patient groups (B0, B1, B2, B3). In our
study population gender and number of TMZ cycles are
not predictive of disease control, while time after the
end of radiotherapy and second surgery are independent
treatment-related risk factors. These data could be useful
to plan prospective and randomized studies to better de-
fine the role of chemotherapy in the combination treat-
ment strategy of an heterogeneous cancer, like GBM.
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